gdc
Gastric Cancer

Drugs for GIST (Gastrointestinal Stromal Tumor)

Here are the drugs and financial support services available to patients receiving treatment for GIST (Gastrointestinal Stromal Tumor).
2019 Patient Guide to Cancer Support Services

Gleevec (imatinib mesylate) Tablets

Drug company: Novartis
800-245-5356

Gleevec is a kinase inhibitor used for the treatment of patients with Kit (CD117)-positive unresectable, recurrent and/or metastatic gastrointestinal stromal tumor (GIST), and as an adjuvant treatment.

Novartis’ Patient Assistance NOW Oncology offers 3 financial assistance programs for patients using Gleevec:

Gleevec Patient Support Program

This program offers patient counselors, educational information, and financial assistance resources, such as the Gleevec $10 Co-Pay Card.

Gleevec $10 Co-Pay Card

Patients with private insurance may pay only $10 for a 30-day supply of Gleevec, with a maximum of $10,630 for a 30-day supply and up to an annual maximum of $30,000.

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Gleevec for free through the Novartis Patient Assistance Foundation. To be eligible for financial assistance, the patient must be a US citizen and must provide proof of income that meets the financial eligibility requirements. Eligible patients may receive Gleevec for free until a prescription drug coverage becomes available to them.

Stivarga (regorafenib) Tablets

Drug company: Bayer
866-639-2827

Stivarga is a kinase inhibitor used for the treatment of patients with locally advanced, unresectable or metastatic GIST.

Bayer offers 2 financial assistance programs for patients using Stivarga:

STIVARGA $0 Co-Pay Program

Through this program, patients with private insurance will have a $0 copay for Stivarga, up to $25,000 per patient annually.

REACH Patient Assistance Program

Uninsured or underinsured patients who are prescribed Stivarga should contact the Resources for Expert Assistance and Care Helpline (REACH) services counselor to possibly qualify for free medication.

Sutent (sunitinib malate) Capsule

Drug company: Pfizer
877-744-5675

Sutent is a kinase inhibitor used for the treatment of patients with GIST.

Pfizer Oncology Together offers 2 financial assistance programs for patients using Sutent:

Pfizer Oncology Together Co-Pay Savings Program

This Pfizer program assists eligible patients with private insurance so that their copay for Sutent is $0 monthly, with a maximum savings of up to $25,000 annually.

Pfizer Patient Assistance Program

This program serves patients who are either uninsured or those with government insurance. Uninsured patients may qualify to receive Sutent for free or at a savings. Eligible patients with government insurance who cannot find independent charitable foundation support may receive Sutent for free.

Table. Drugs Prescribed for GIST (Gastrointestinal Stromal Tumor)

  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services



Recommended For You
FDA Approvals, News & UpdatesGastric Cancer
Lonsurf Approved for Metastatic Gastric or Gastroesophageal Junction Cancer
In February 2019, the FDA approved Lonsurf for the treatment of patients with metastatic gastric (stomach) cancer or gastroesophageal junction adenocarcinoma. This drug was previously approved only for patients with metastatic colorectal cancer.
Gastric Cancer
Drugs for Gastric/Gastroesophageal Junction Cancer
Here are the drugs and financial support services available to patients receiving treatment for Gastric/Gastroesophageal Junction Cancer.
Gastric CancerPatient Stories
A Disney Childhood Until Cancer Enters Stage Left
By Cathy Freeman
Cathy Sherman Freeman’s father, who was Head of Publications at Walt Disney Studios, passed away of gastrointestinal stromal tumor (GIST), the same rare cancer she was diagnosed with several years ago.
Last modified: March 7, 2019

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country